16 NOV 2023 | US | Approval Alert: AZ’s Truqap® (capivasertib) plus Faslodex® FDA Approved to Treat Advanced...
BioBlast w/e 17 Nov 23
read more
Home / News / Pearce IP Blog
ALL BLOGS BY
Naomi Pearce
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.
See Naomi's full profile
Confectionary chronicles: glucose jelly bean trade mark application appealed
On 9 August 2023, the Registrar of Trade Marks handed down a decision in favour of Nova Pharmaceuticals Australasia...
BioBlast w/e 10 Nov 23
10 NOV 2023 | EU | CHMP Positive Opinion for 8mg Eylea® (Aflibercept) Bayer announced that the EMA’s Committee for...
Generics take Sandoz Rivaroxaban Loss to Heart – Bayer’s Rivaroxaban Patents Valid & Sandoz AU Launch Delayed by Injunction (Appeal Pending)
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BREAKING NEWS: Bayer Rivaroxaban patents survive first AU challenge by Sandoz with ~150 generic products approved
With over 150 rivaroxaban products approved (9 of them for Bayer), the outcome of the Sandoz challenge to the validity...
BioBlast w/e 03 Nov 23
01 NOV 2023 | EU | Fresenius Kabi’s Launches First EU Tocilizumab Biosimilar Fresenius Kabi announced it has...
A hard lesson learnt: Commonwealth v Sanofi
The Australian government has made numerous claims for damages against patentees for savings forgone when an...
BioBlast w/e 27 Oct 23
27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it...
BioBlast w/e 23 Oct 23
23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s...
BioBlast w/e 15 Oct 23
15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on...
Advanta succeeds again in second extension of time application opposed by Nufarm
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
Breakthrough Mining Innovator Globaltech wins AU Patent Battle against Market Leader Reflex
An Australian Court has found in favour of Globaltech which solved a mining problem with an elegant solution. An important lesson from this decision is that driving IP innovation can be central to maintaining a market-leading position.
BioBlast w/e 07 Oct 23
07 OCT 2023 | Samsung Bioepis Presents Switching Study Results for SB15, Biosimilar to Regeneron’s Eylea®...
When perceiving the problem is the inventive step – complacent market leader Reflex infringes disruptor Globaltech’s valid patent
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.
BioBlast w/e 02 Oct 23
02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19...
Zoetis Vaccine Patent Survives Opposition Appeal by the Hair of its Chinny Chin Chin
In this patent infringement/validity dispute, Hanwha failed to establish that REC infringed its “old Act” Australian patent No 2008323025, and its dependant ACL claims were dismissed.